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Abstract
Background: Cancer stem cells (CSCs) are thought to be responsible for tumor regeneration after chemotherapy, although
direct confirmation of this remains forthcoming. We therefore investigated whether drug treatment could enrich and
maintain CSCs and whether the high tumorogenic and metastatic abilities of CSCs were based on their marked ability to
produce growth and angiogenic factors and express their cognate receptors to stimulate tumor cell proliferation and
stroma formation.
Methodology/Findings: Treatment of lung tumor cells with doxorubicin, cisplatin, or etoposide resulted in the selection of
drug surviving cells (DSCs). These cells expressed CD133, CD117, SSEA-3, TRA1-81, Oct-4, and nuclear b-catenin and lost
expression of the differentiation markers cytokeratins 8/18 (CK 8/18). DSCs were able to grow as tumor spheres, maintain
self-renewal capacity, and differentiate. Differentiated progenitors lost expression of CD133, gained CK 8/18 and acquired
drug sensitivity. In the presence of drugs, differentiation of DSCs was abrogated allowing propagation of cells with CSC-like
characteristics. Lung DSCs demonstrated high tumorogenic and metastatic potential following inoculation into SCID mice,
which supported their classification as CSCs. Luminex analysis of human and murine cytokines in sonicated lysates of
parental- and CSC-derived tumors revealed that CSC-derived tumors contained two- to three-fold higher levels of human
angiogenic and growth factors (VEGF, bFGF, IL-6, IL-8, HGF, PDGF-BB, G-CSF, and SCGF-b). CSCs also showed elevated levels
of expression of human VEGFR2, FGFR2, CXCR1, 2 and 4 receptors. Moreover, human CSCs growing in SCID mice stimulated
murine stroma to produce elevated levels of angiogenic and growth factors.
Conclusions/Significance: These findings suggest that chemotherapy can lead to propagation of CSCs and prevention of
their differentiation. The high tumorigenic and metastatic potentials of CSCs are associated with efficient cytokine network
production that may represent a target for increased efficacy of cancer therapy.
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Introduction
In recent years, substantial experimental evidence has been
generated in support of the role of a small population of self-
renewing cells that could sustain malignant growth [1,2]. This
population was termed cancer-initiating cells or cancer stem cells
(CSCs) for their high capacity for self-renewal, multilineage
differentiation, and superior levels of malignancy. CSCs have
been identified and isolated in various malignancies including
breast, brain, prostate, pancreatic, lung, and colon cancer [3–11].
CSCs were identified utilizing flow-cytometry-based cell sorting
and NOD/SCID mice xenografting. CSCs express tissue-specific
cell surface markers: e.g., breast CSCs express CD44+/CD24low
[3], and brain, prostate, lung and pancreatic CSCs express
CD133+ [2,4,7,8,10].
Flow-cytometry-based cell-sorting which enables the isolation of a
‘‘side population’’ (SP) with enriched cancer stem cell activity was
described by Goodell et al [12]. SP cells are characterized by distinct
low Hoechst 33342 dye staining, attributed to the expression of
ABCG2, an ATF-binding cassette (ABC) transporter [13]. SP cells
also demonstrate a greater tumorigenic capacity than non-SP cells
[13–15]. Flow-cytometry-based methods of sorting CSCs, using
specific tissue CSC markers as well as the formation of spherical
clusters of self-replicating cells [16–18], permit the isolation of a cell
population enriched in early progenitor/stem cells.
Due to their high drug resistance and tumorigenicity, CSCs are
thought to be responsible for tumor regeneration after chemotherapy
[19,20], although direct confirmation of this is still forthcoming. We
therefore hypothesize that CSCs can be enriched and subsequently
isolated from tumor cell populations following drug treatment.
In the present study drug surviving cells (DSCs) were isolated
from human cancer cell lines treated with cisplatin, doxorubicin,
or etoposide. Isolated DSCs exhibited high clonogenic capacities,
enrichment with SP cells, expression of CSC cell surface and
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embryonic stem cell markers, a capacity for self-renewal, the
generation of differentiated progeny, and high tumorigenic
potential following SCID mice transplantation. We concluded
that these DSCs were CSCs.
It has also been suggested that CSCs have high metastatic
potential [21]. Recently, the relationship between pancreatic CSCs
and tumor metastasis was demonstrated [8]. We demonstrated that
drug isolated lung CSCs have high metastatic potential.
It continues to be unclear what properties of CSCs confer
increased tumorigenicity and metastatic potential. We hypothesized
that the tumorigenic and metastatic abilities of CSCs were based on
their marked ability to produce growth and angiogenic factors, which
stimulate tumor cell proliferation as well as promote formation of the
tumor vascular system in order to provide oxygen and nutrients for
local tumor growth or distant growth after dissemination of tumor
cells into different anatomical locations. Thus, the highly efficient
production of growth and angiogenic factors is a fundamental
property of tumor-initiating cells. VEGF is a potent angiogenic factor
[22], while growth factors such as bFGF, EGF, and HGF can
stimulate proliferation of not only tumor cells but also endothelial cells
and thus manifest proangiogenic and antiapoptotic effects [23]. Some
data indicate that chemokines, such as IL-8 (CXCL8), MCP-1
(CCL2), and RANTES (CCL5), not only stimulate migration, but
also proliferation of tumor and stromal cells, including endothelial
cells [24]. Recently it was shown that IL-8 exhibits strong angiogenic
activity via transactivation of VEGF receptor 2 (VEGFR2) [25].
Thus, different types of tumor producing factors (cytokines,
chemokines, angiogenic and growth factors) have overlapping
functions in promoting tumor growth. Numerous experimental and
clinical data indicate that neutralization of growth or angiogenic
factors, or blocking their receptor signaling, could inhibit tumor
growth, confirming the importance of these factors in tumor cell
proliferation [26]. Thus, production of growth and angiogenic factors
by CSCs appears crucial for their tumorigenic and metastatic
potentials. However, this CSC cytokine and growth/angiogenic
factor network had not been previously investigated.
Therefore, in the present study, we performed a comprehensive
analysis of various cytokines, chemokines, and growth factors
produced by parental H460 tumor cells and isolated CSCs using
multiplex xMAP technology (Luminex Corp., Austin, TX), which
allows simultaneous analysis of numerous soluble factors. This
analysis was performed in vitro on cultured cells and in vivo utilizing
the human tumor xenografted model in SCID mice. Human
tumors growing in SCID mice consist of human tumor cells and
murine stroma. Sonicated extracts of the xenografted human
tumors contained cytokines produced by human tumor cells as
well as by murine stromal cells. Concentrations of each type of
cytokines can be analyzed using multiplex kits developed
specifically for the detection of human or murine cytokines. This
could provide information about the cytokine network produced
by CSCs and their ability to stimulate stroma formation.
Our studies demonstrate that drug surviving lung tumor cells
have the characteristics of CSCs, and produce elevated levels of
multiple cytokines, chemokines, growth and angiogenic factors
and their receptors. These findings bring new insight to our
understanding of the mechanisms responsible for high tumorigenic




Human cultured cancer cell lines, OVCAR-3 (ovarian), MCF-7
(breast), and H460 (lung), were obtained from the American Type
Culture Collection (ATCC, Rockville, MD, USA). Cells were
grown in culture media, as recommended by ATCC, supplement-
ed with 20% FBS (Millipore Inc., Billerica, MA).
Reagents
Cisplatin, doxorubicin, etoposide, and Hoechst 33342 were
from Sigma-Aldrich (Sigma-Aldrich, St. Louis, MO). Fluoro-
chrome-conjugated antibodies against human CD24, CD34,
CD44, CD24, CD117, CD90, VLA-4, and VLA-5 were from
Beckman Coulter (Fullerton, CA). Antibodies against FGFR2,
VEGFR1, VEGFR2, and CXCR1, 2, 4 were from R&D Systems
INC. (Minneapolis, MN). The antibody against VLA-6 was
obtained from AbD Serotec (Raleigh, NY). Antibodies against CD
133 and cytokeratins 8/18 were from Abcam Inc. (Abcam,
Cambridge, MA). Alexa FluorH-488 conjugated mouse antihuman
TRA-1-60, TRA-1-81, SSEA-1-4, and the antibody against
human b-catenin were purchased from BD Biosciences Inc. (San
Diego, CA). The antibody against phosphor-b-catenin was from
Cell Signaling Technology Inc. (Beverly, MA). An embryonic stem
(ES) marker sample kit, designed for detection of SSEA-1, 3, 4,
TRA-1-60, TRA-1-81, and Oct-4, was obtained from Chemicon
International (Tamecula, Ca). Alexa FluorH-488 phalloidin and
secondary Abs conjugated with Alexa 488, 546, and 680 were
from Molecular Probes (Invitrogen, Carlsbad, CA).
Clonogenic assays
Cells were plated at a density of 10–50 cells/cm2 in 100 mm2
Petri dishes or at a density of 0.5 cells/well in 96-well plates, and
cultured for 14 days. For colony counting, cells were fixed and
stained with Coomassie brilliant blue.
Flow cytometry analysis
For side population (SP) analysis of cells we used standard
protocol [12]. To inhibit ABCG2 transporter, 10 mM fumitre-
morgin C (Calbiochem/EMD Biosciences, Inc., San Diego, CA)
was added 10 min before Hoechst addition. In some experiments,
verapamil (50 mmol/L) was added with dye to confirm the SP
(data not shown). Cells were analyzed using a MoFlo cytometer
(Cytomation, Fort Collins, CO). Excitation of Hoechst dye was
performed using a UV laser at 351 to 364 nm; the fluorescence
was measured with a 515-nm side population filter (Hoechst blue)
and a 608 EFLP optical filter (Hoechst red). Instrument gains were
adjusted to set the main cell cohort, which comprises most of the
cells containing one copy of DNA at the center of the plots.
CD133+ cells were sorted from parental lung cancer H460
population using MoFlo cytometer and standard protocol for
immunofluorescent staining.
Cell staining procedure for Cellomics ArrayScan
automated imaging
Cells were fluorescently stained as described [27]. Briefly, cells
were grown in 96-well plates, washed with FACS buffer, incubated
with antibodies against CD24, CD34, VLA-4, VLA-5, VLA-6,
CD44, CD87, CD90, CD117, FGFR2, VEGFR1 and VEGFR2
conjugated with FITC, PE, or PC5, for 1 h, fixed in 2% PFA for
20 min, washed in PBS, and stained with Hoechst 33342. To test
CD133, CXCR1, CXCR2 and CXCR4 expression, cells were
incubated with respective primary antibodies and then with
secondary antibodies conjugated with Alexa 488, 546, or 680
fluorochromes (Molecular Probes/Invitrogen) for 1 h. Cells were
then stained with Hoechst 33342.
To detect intracellular proteins, cells were fixed, permeabilazed,
and incubated with primary antibodies against embryonic stem
Lung CSCs and Cytokine Network
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cells markers, b-catenin, and cytokeratins 8/18 for 1 h and with
secondary antibodies conjugated with Alexa 488, 546, or 680
fluorochromes (Molecular Probes/Invitrogen) for 1 h. For actin
cytoskeleton staining, cells were incubated with Alexa Fluor 488
Phalloidin for 1 h. Cell nuclei were then stained with Hoechst
33342 at 2 mg/ml for 20 min to identify individual cells and to
optimize focusing.
To stain tumor spheres, all manipulations were done under the
microscopic control: tumor spheres were gently placed into
individual wells of ultra low adherent 96 well plates, and
incubation with primary and secondary antibodies was the same
as described above for the adherent cultures.
All incubation and fixation procedures were performed at room
temperature.
Cellomics ArrayScan automated imaging
The Cellomics ArrayScan HCS Reader (Cellomics/ Thermo-
Fisher, Pittsburgh, PA) was utilized to collect information on
distribution of fluorescently labeled components in the stained
cells. The ArrayScan HCS system scans multiple fields in
individual wells, acquiring and analyzing each of the cell images
according to defined algorithms. The scanner is equipped with
emission and excitation filters (XF93, Omega Optical, Brattleboro,
VT, USA) for selectively imaging fluorescent signals. Data were
captured, extracted, and analyzed with ArrayScan II Data
Acquisition and Data Viewer version 3.0 (Cellomics), Quattro
Pro version 10.0.0 (Corel, Ottawa, Ontario, Canada), and MS
Excel 2002 (Microsoft, Redmond, WA).
Culture of lung cancer spheres
Suspension growth was assessed in methyl cellulose-based (MC-
based) medium as described [16,17]. Briefly, H460 cells and drug
selected cells were resuspended in 0.8% MC-based serum free
medium (Stem Cell Technologies, Vancouver, Canada) supple-
mented with 20 ng/mL EGF (BD Biosciences), bFGF, and 4 mg/
mL insulin (Sigma) and plated at 500–10000 cells/mL in ultra low
adherent 24–96 well plates (Corning, Corning, NY). EGF, bFGF
(20 ng/mL), and insulin (4 mg/mL) were added every second day
for two weeks. The medium was replaced or supplemented with
fresh growth factors twice a week. In order to assess the self-
renewing potential of the cells, spheres were collected by gentle
centrifugation, dissociated into single cell suspensions, filtered and
cultured under conditions described above.
Differentiation
Cells dissociated from spheres (third generation) were plated at
16104 cells/mL on 96-well plates precoated with Collagen IV (BD
Biosciences) in culture media supplemented with 10% FBS
without growth factors and transferred into new plates when
cultures reached confluence. To test the self-renewing potential of
differentiated cells, cells were transferred into semisolid serum-free
media supplemented with EGF, FGF, and insulin and their ability
to form tumor spheres was evaluated as described above. To
perform phenotypic characterization of cells from spheres and cells
after differentiation, cells were seeded in 96-well plates (56103
cells/well) and stained with various antibodies as described above.
Chemotherapy resistance studies
H460 parental cells, cells obtained from lung cancer spheres, and
three weeks after CSCs differentiation cells were plated into 96-well
plates precoated with Collagen IV (BD Biosciences) and cultured in
RPMI 1640 media supplemented with 10% FBS. After 24 h
doxorubicin and cisplatin were added at the final concentrations
(0.016–025 mg/ml and 0.165–3.30 mg/ml, respectively). After 72 h
of treatment, cells were stained with Hoechst 33342, and the
number of cells per well were counted with Cellomics Array Scan
VTI (Cellomics/ ThermoFisher, Pittsburgh, PA), as described [27].
Migration and invasion assay
The migration and invasion activity of tumor cells in response to
human recombinant IL-8 (100 ng/ml) was measured in BD
BioCoat Matrigel Invasion Chambers (BD Biosciences, San Jose,
CA) according to manufacturer protocol.
Analysis of tumorigenic and metastatic properties of
DSCs and H460 tumor cells
Experiments were carried out in accordance with guidelines
provided by the Pittsburgh University Institutional Animal Care
and Use Committee (IACUC) and the National Institute of Health
Guide for the Care and Use of Laboratory Animals. SCID mice,
728 weeks old (Jackson Laboratories, Bar Harbor, ME), were
maintained in the animal facility of the University of Pittsburgh
Cancer Institute (UPCI).
To compare tumorigenic properties, H460 cells and DSCs were
harvested and injected (in 200 ml of PBS) subcutaneously (s.c.) into
SCID mice at concentrations of 56103–56105 cells per mouse (5
mice per group) without Matrigel. Tumors were measured twice a
week. Mice were sacrificed when their tumors measured
approximately 2 cm in diameter.
To analyze the ability of H460 cells and CSCs to form
metastases, 56104 cells were inoculated intravenously (i.v.) into the
tail vein of SCID mice. The SCID mice were T, B, and NKT cell-
deficient but had active NK cells that could eliminate human
tumor cells circulating in the blood stream. To deplete NK cells,
SCID mice were inoculated intraperitoneally (i.p.) with 0.2 ml of
anti-asialo GM1 IgG (diluted 1:20) 24 h before i.v. inoculation of
tumor cells [28]. After 60 days, mice were sacrificed; lungs, livers,
and kidneys were removed and fixed in the Bouin’s solution; and
metastatic nodules were counted under a dissecting microscope.
Preparation of tumor extracts
Tumors grown s.c. in SCID mice were removed and snap-
frozen in liquid nitrogen. Frozen tumor tissues were cut, sonicated
for 20 s, and centrifuged at 15,000 g for 10 min to remove cell
debris. Tumor extracts were stored at 280 uC.
Multiplex analysis of cytokines
Analysis of human cytokines and growth factors in cell culture
medium and in sonicated tumor lysates was performed using
multiplexing xMAP technology (Luminex Corp., Austin, TX).
Multiplex kits for detection of 49 human cytokines: IL-1a, IL-1b,
IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-10, IL-12p40, IL-13, IL-15,
IL-17, GM-CSF, IFN-a, TNFa, MCP-1, MCP-2, MCP-3, IP-10,
MIP-1a, MIP-1b, RANTES, VEGF, bFGF, G-CSF, EOTAXIN,
HGF, MIG, GROa, sIL-2R, sVCAM-1, CTACK, LIF, M-CSF,
NGF, PDGF-BB SCF, SCGF-b, SDF-1a, TNF b, TRAIL IFN-c,
EGF, TNFRI, TNFRII, DR5, IL-1Ra, and sIL-6R were
purchased from BIO-RAD Laboratories (Hercules, CA). Multi-
plex kit for detection of sFas, sFasL, TGFa, Fractalkine, sCD40L,
TRAP, CS154, MIF, sVCAM-1, sICAM-1, MPO, Adiponectin,
MMP-9, and tPAI-1 were purchased from Linco/Millipore (St.
Louise, MO). The kit for detection of MMP-2 and MMP-3 was
purchased from R&D Research (Minneapolis, MN). The multi-
plex kit for detection cancer antigens CEA, CA-125, CA 19-9, CA
15-3, CA72-4, AFP as well as mesothelin, IGFBP-1, kallikrein 10,
EGFR, ErbB2, and Cyfra 21-1 were custom-made at the UPCI
Lung CSCs and Cytokine Network
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Luminex Core Facility (www.upci.upmc.edu/facilities/luminex).
Mouse cytokines were analyzed using 19-plex kit for IL-1a, IL-1b,
IL-2, IL-4, IL-5, IL-6, IL-10, IL-13, IL-17, IFN-c, MIG, GM-
CSF, MIP-1a, IL-12p40/p70, KC, TNFa, MCP-1, VEGF, and
bFGF (Invitrogen/Biosource). Analyses of tumor supernatants and
sonicated tumor extracts were performed in 96-well micro plate
format according to manufacturers’ protocols as previously
described [29]. Parts of tumor extracts were used for protein
analysis. Data were presented as mean6SD pg/mg of protein.
Statistical analysis
All experiments were repeated at least three times. Comparisons
between values were performed using a two-tailed Student’s t-test.
For the comparison of multiple groups, a one- or two-way
ANOVA test was applied. Statistical analysis of the metastatic
nodules was performed using Mann-Whithey test. For all statistical
analyses, the level of significance was set at a probability of ,0.05.
Results
Isolation of CSCs based on their resistance to
chemotherapeutic drugs
Ovarian OVCAR-3, breast MCF-7, and non-small cell lung
cancer (NSCLC) H460 cells were treated with cisplatin (1–5 mM),
etoposide (1–5 mM), or doxorubicin (0.067–0.125 mg/ml) for 3
days. A vast majority of the cells died. Over the next 7 days some
surviving cells resembled senescent cells with enlarged and
flattened morphology [30]. These ‘‘senescent’’ cells grew larger
in size and died during weeks 2–4. During the first week after drug
treatment, small, round, or spindle-shaped cells with lower
adherence were detected, and their growing colonies gradually
replaced the ‘‘senescent’’ cells in drug-treated cancer cell
populations (Figure 1A). We assumed that drug surviving small
cells were CSCs. To verify this, the expanded drug surviving cells
(DSCs) were analyzed for their clonogenic capacity, SP phenotype,
CSC markers, self-renewal capacity, ability to differentiate, and
tumorigenic and metastatic potential.
Clonogenicity of DSCs
The clonogenic capacity of parental H460, OVCAR3, and
MCF7 cells and DSC populations was tested as described in
Materials and Methods. Less than 40% of parental cells were able
to form clones, whereas the clone-forming capacity of DSCs was
more than twofold higher (Figure 1B).
Analysis of SP phenotype
Analysis of SP fractions revealed that tested parental cell lines
differed in the proportion of SP fraction, ranging from 0.6% in
OVCAR3, 0.5% in MCF7, to 5.2% in H460 cells (Figure 1C). SP
cell fractions were substantially higher in DSC populations varying
from 10.7% in MCF7, 15.6% in OVCAR3 to 35.3% in H460. A
distinct low Hoechst 33342 staining of SP cells has been attributed
Figure 1. Selection of DSCs populations from human carcinoma cell lines. A, Morphology of parental MCF7, OVCAR3 and H460 cells and drug
survived cells (DSCs). MCF-7 and H460 cells were treated with doxorubicin (0.125 mg/ml); OVCAR-3 cells were treated with cisplatin (3.3 mg/ml). After
48 h drugs were removed and drug-surviving cells (DSCs) were cultured for 3–4 weeks. B, Increased colony formation by DSCs isolated from parental
MCF7 (breast), H460 (lung) and OVCAR-3 (ovarian) cancer cell lines. Cells were seeded 0.5 cell/per well in 96-well plates with culture media
supplemented with 10% of FBS and cells were grown for two week. The percentage of colony formation was calculated. ***-P,0.001. C, Analysis of
side population (SP) in DSCs and parental MCF7, OVCAR-3 and H460 cell lines. Tumor cells were stained with 5 mg/ml Hoechst33342 (HO). Some cells
were pretreated with 10 mM fumitremorgin C (FTC) for 10 min prior to Hoechst addition (HO+FTC). Cells were resuspended in RPMI with 20% FBS and
2 mg/ml propidium iodide and sorted using MoFlo cytometer. Data for viable cells were analyzed for parametric correlations and annotated using FCS
Express.
doi:10.1371/journal.pone.0003077.g001
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to the expression of ABCG2, an ATF-binding cassette (ABC)
transporter [13]. To evaluate ABCG2 transporter activity,
fumitremorgin C (FTC), an ABCG2 specific inhibitor was used.
The SP fraction of DSC cells decreased significantly in the
presence of FTC (Figure 1C), thus confirming upregulation of
ABCG2 transporter in DSCs.
Analysis of CSCs and embryonic stem cell (ESC) markers
The Cellomics Array Scan HCS Reader (Cellomics/ Thermo-
Fisher) was used for imaging and analysis of expression of CSCs and
embryonic stem cell markers in DSCs. This approach is based on a
combination of microscopy and flow cytometry methods in a 96-
well format. The advantages of the approach include: 10 times less
cells are needed than for flow cytometry analysis, multi-spectral
fluorescence micro-imaging is automated, and images are stored,
visualized and analyzed using powerful software applications.
The analysis revealed that the DSC population from MCF-7
cells were CD44 positive with low levels of CD24 expression (data
not presented), which corresponds to the previously identified
phenotype of breast CSCs [3]. The DSCs from the ovarian
OVCAR-3 line expressed CD44+ and ES marker Oct-4 (data not
shown).
To date, human lung CSCs are poorly characterized [10,15]. We
therefore focused next on the characterization of CSC properties in
DSCs from lung H460 tumor cell line. Analysis of CD34, CD24/
CD44, CD87, and CD90 cell surface markers showed no
differential expression between H460 parental and DSC popula-
tions (data not shown), whereas isolated human lung DSCs were
enriched for the CD133+ population (Figures A, B). We next
analyzed the expression of embryonic stem cell (ESC) markers,
podocalyxin antigens, TRA-1-60, TRA-1-81, glycolipid antigens,
the stage-specific antigens SSEA-3, 4, and transcription factor Oct-
4, in H460 parental cells and isolated DSCs. Higher expression of
TRA-1-81, SSEA-3, and Oct-4 was found in isolated DSCs as
compared to parental H460 cells (Figure 2C, D), supporting our
assumption that DSCs manifest markers associated with SCs.
Figure 2. Analysis of CD133, embryonic stem cell (ESC) markers and cytokeratins 8/18 expression in H460 cells and DSCs. H460 cells
and DSCs, growing in 96-well plates, were fixed and incubated with primary Abs against CD133, TRA-1-81, SSEA-3, Oct-4, or cytokeratins8/18 and
then with secondary Abs. Cell nuclei were stained with Hoechst 33342. Cell images were acquired using the Cellomics ArrayScan HCS Reader (20X,
40X objectives) and analyzed using the Target Activation BioApplication Software Module. A, Immunofluorescent images of tumor cells. B, Fluorescence
intensity (pix) of CD133 plotted against object area. Each point represents a single cell. Cells to the right of the red line are CD133+ (above IgG control
staining). C, Images of tumor cells immunofluorescently stained tumor cells for TRA-1-81, SSEA-3 and Oct-4 ES cell markers. D. Fluorescence intensity of
TRA-1-81, SSEA-3 and Oct-4, plotted against object area. Each point represents a single cell. Cells to the right of the red line are positive (above IgG
control staining). E,Images of immunofluorescently stained tumor cells for cytokeratins8/18. F, Fluorescence intensity of cytokeratins8/18 in H460 cells
(black dots) and DSCs (grey dots) plotted against object area.
doi:10.1371/journal.pone.0003077.g002
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Low levels of differentiation marker cytokeratins (CK)
expression in DSCs
Lung cancer cells are known to express type I CK18 and type II
CK8 cytokeratins, known differentiation markers in these cells
[31]. We compared expression of CK8/18 in H460 cells and
DSCs. In comparison to parental H460 cell line, DSCs expressed
very low levels of CK8/CK18 (Figure 3D, E), indicating a low
differentiation status of the isolated DSCs.
b-catenin expression
Wnt signaling proteins have been shown to play a role in
controlling stem cell self-renewal. b-catenin is a key player in the
Wnt pathway, transmitting Wnt signals to the nucleus and playing a
crucial role in tumorigenesis [32–34]. Here we analyzed the
intracellular distribution of b-catenin in H460 cells and DSCs.
DSCs showed substantially higher levels of total and nuclear b-
catenin than parental H460 cells (Figure 3A,B), whereas phosphor-
ylated b-catenin was present at low level in DSCs as compared to
parental H460 cells (Figure 3C). It is known that in differentiated
cells where Wnt signaling is absent, the level of b-catenin is
regulated by a multiprotein ‘‘destruction complex’’ which binds and
phosphorylates b-catenin, thus targeting it for ubiquitination and
proteolytic degradation [32]. In stem cells where Wnt ligands are
presented, this ‘‘destruction complex’’ is inhibited, preventing b-
catenin phosphorylation and degradation, leading to stabilization
and nuclear translocation of b-catenin [32–34]. Thus, high levels of
nuclear accumulation of b-catenin and low levels of phosphorylated
b-catenin suggest the active Wnt signaling in DSCs.
Analysis of cell migration and expression of VLA
adhesion molecules
Our morphological analysis of DSCs and parental H460 cells
revealed differences in cell shape and adhesion properties,
suggesting potential differences in their cytoskeletal organization.
To test this hypothesis, we used Alexa 488 phalloidin to visualize
the F-actin. As shown in Figure 3D, parental H460 cells have a
round shape and uniform distribution of the F-actin in cytoplasm,
whereas some DSCs have lamellipodial extension and actin spikes
at the leading edge of the cells. These results suggest that DSCs
have a greater ‘‘migratory phenotype’’ than parental H460 cells.
We investigated the migratory capacity of H460 cells and DSCs
using an in vitro migration and invasion assay using the IL-8 as the
chemoattractant. Whereas, only 13.7% of parental H460 cells
invaded through the Matrigel, 87.5% of DSCs were invasive.
Adhesion molecules, including integrins, facilitate cell survival
signaling and are involved in motility, intercellular adhesion,
Figure 3. Analysis of b-catenin intracellular distribution in H460 cells and DSCs. Cells were fixed and incubated with Alexa FluorH 488
phalloidin or with primary Abs against b-catenin and with secondary Alexa Fluor 488 conjugated Abs. Next cells were stained with Hoechst33342. Cell
images were acquired using the Cellomics ArrayScan HCS Reader (20X objective) and analyzed using the Compartment Analysis BioApplication
Software Module and the Target Activation BioApplication Software Module. A, Images of H460 cells and DSCs immunofluorescently stained for b-
catenin (A). B, An average fluorescence intensity of nuclear b-catenin in H460 (black line) and DSCs (grey line).C, An average fluorescence intensity of
cellular phosphor- b-catenin in H460 (black line) and DSCs (grey line). D, Cytoskeleton images of H460 cells and DSCs immunofluorescently stained for
phalloidin and Hoechst33342.
doi:10.1371/journal.pone.0003077.g003
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chemotaxis, and metastasis [35]. We compared the expression of
integrins VLA-4, VLA-5, and VLA-6 in H460 cells and DSCs. We
found that DSCs had significantly higher levels of VLA-5 and lower
levels of VLA-6 as compared with parental cells, whereas VLA-4
levels were similar in both subpopulations (Figure 4D). Deprivation of
tumor cell adhesion can trigger apoptosis. This form of apoptosis,
induced as a result of the loss of cell’s adhesion to a substrate, was
termed anoikis. The low adhesion of DSCs may decrease their
dependence on some surviving signals and lead to resistance to
anoikis. Anoikis-resistant cells showed higher metastatic ability [36].
We observed that lung DSCs cultured under nonadherent conditions
(low adherence plates) were resistant to anoikis, whereas all the H460
cells died under the same conditions.
Chemotherapy selectively enriches for self-renewing
lung cancer cells
The ability to self-renewal and generate differentiated progeny
are fundamental properties of CSCs. Tumor sphere generation is
an in vitro assay of self-renewal potential [37]. Therefore, we
assessed the self-renewal properties of DSCs by their ability to
form tumor spheres when cultured in serum-free media and non-
adherent conditions, as described in Materials and Methods. The
vast majority of parental H460 cells died; however, a small
proportion, 2.16%, of parental H460 cells survived and generated
floating spherical colonies after 10–15 days in culture (Figure 5, A,
B). In contrast, 63.71% of DSCs formed spheres. Moreover, the
spheres, which developed from DSCs, grew faster and larger than
spheres developed from untreated parental H460 cells. We next
compared the self-renewal potential of cells derived from first
generation spheres. Single cell suspensions were prepared from
tumor spheres, transferred onto low adherence plates and cultured
in serum free stem cells medium as described in Material and
Methods. We found that spheres derived from DSCs produced a
higher proportion of self-renewing (sphere forming) cells in
comparison with sphere-derived H460 cells (Figure 5, B). Cells
from spheres, regardless of whether they were derived from DSCs
or parental H460 cells, expressed cancer stem cell markers
CD133, CD117 (c-kit), and ESCs marker TRA 1-81 (Figure 5C).
Analysis of DSCs ability to generate a differentiated
progeny
The differentiation potential of cells from third generation lung
cancer spheres was evaluated. Cells dissociated from spheres were
cultured in RPMI 1640 medium supplemented with 10 % FBS in
plates precoated with Collagen IV to improve cell adhesion. After
3 weeks of culture under adherent conditions, the cells acquired
the typical morphologic features of parental H460 cells with
increased expression of the differentiation marker cytokeratins 8/
18 and loss of expression of CSC marker CD133 (Figure 6A).
Next, we analyzed the self-renewal potential of differentiated
cells. After 3 weeks of culture under adherent conditions, cells were
transferred onto low-adherent plates and cultured in serum free
stem cell medium. Tumor sphere formation was evaluated. Cells
maintained under differentiating conditions for 3 weeks demon-
strated a substantial reduction in their ability to form spheres,
indicating a reduction in their self-renewal potential (Figure 6B).
Figure 4. Expression of adhesion molecules, VLA-4(CD49d), VLA-5(CD49e), VLA-6(CD49f), by H460 cells and DSCs. Cells were
incubated with Abs against VLA-4-FITC and VLA-6-PC5 or VLA-5-FITC and VLA-6-PC5. Cell images were acquired using the Cellomics ArrayScan HCS
Reader (20X, 40X objectives) and analyzed using the Target Activation BioApplication Software Module. A, Immunofluorescent images of VLA4/VLA6
(left) and VLA-5/VLA-6 (right) expression in H460 and DSCs cells (40X objective). B-D, An average fluorescence intensity of VLA-4(B), VLA-5(C) and VLA-6(D)
in H460 cells (black line) and DSCs (grey line).
doi:10.1371/journal.pone.0003077.g004
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Effect of chemotherapy on parental H460 cells, self-
renewing and differentiated lung cancer cells
We considered the question of whether chemotherapeutic drugs
could select cells with self-renewing characteristics from already
differentiated tumor cells. Cells that were differentiated for 3 weeks
under adherent condition were treated with cisplatin (1 mM) for
two days and high proportion of these tumor cells were killed by
drug. The ability of cisplatin surviving cells to form tumor spheres
in serum free medium supplemented with growth factors was
analyzed. Untreated differentiated tumor cells displayed a low
ability to form spheres, while cells that survived cisplatin treatment
showed a high capacity for sphere formation and self-renewal
(Fig. 6B). These data indicate that differentiated progeny of DSCs
acquired drug sensitivity and were eliminated by subsequent re-
exposure to drugs, whereas surviving cells represent a population
with a high self-renewal capacity. To further confirm this
conclusion, parental H460 cells, cells dissociated from tumor
spheres, and cells differentiated in adherent conditions for 3 weeks
were seeded into 96-well plates precoated with Collagen IV, and
cultured for 3 days with different concentrations of doxorubicin or
cisplatin. Surviving cells were counted using the Cellomics Array
Scan. Parental H460 cells were highly sensitive to drugs, while
cells from the tumor spheres were relatively drug-resistant
(Figure 6C). Differentiated cells were more sensitive to drugs than
sphere-derived cells, but slightly more resistant to drugs than
parental H460 cells. These results demonstrate that differentiation
of drug-resistant self-renewal cells is associated with increase their
drug sensitivity. We repeated this cycle. The differentiated cells
that survived drug treatment showed CSC characteristics and self-
renewal. CSCs from the second round of selection were again able
to develop differentiated progenitor cells that showed increased
drug sensitivity as it was found during the first round of drug
treatment (data not shown).
Taken together, all these data strongly indicate that DSCs
express markers conventional for CSCs (CD133), ESC markers
(TRA-1-81, SSEA-3, and Oct-4), low levels of differentiation
markers CK8/18, and demonstrate a capacity for self-renewal and
differentiation.
As shown above (Figure 2) parental H460 population contains
1.8% CD133+ cells. To test whether CD133+ cells from the
parental H460 population share the markers of DSCs, we isolated
CD133+ cells from parental untreated H460 cells using flow
cytometry. Analysis of surface markers, CK8/18 expression, and
the ability to grow in tumor spheres revealed that DSCs and
CD133+ flow cytometry-sorted cells have the same phenotype
(data not shown).
DSCs have high tumorigenic potential
To compare the tumorigenic potential of drug-isolated CSCs in
comparison with H460 cells, SCID mice were inoculated s.c. with
56103–56105 cells without Matrigel which provides artificial
environment, stimulates production of various cytokine, and
angiogenesis. As shown in Table 1, tumor growth was observed
in all mice inoculated with 56103–56105 DSC cells, whereas no
tumor growth was observed after inoculation with 56103 H460
cells. H460 cells grew in four out of five SCID mice inoculated
Figure 5. Chemotherapy selectively enriches for self-renewing lung cancer cells. Parental H460 cells and DSCs (1000 cell/ml) were plated
onto ultra low adherent plates in MC-based serum free media supplemented with growth factors and cultivated as described in Material and
Methods. Tumor spheres generated from single-cell suspension cultures of parental H460 cells and drug survived CSCs were counted after 3 weeks of
culture (1 st generation), and then spheres were dissociated and replated as described in Material and Methods. A, Lung tumor spheres generated from
single-cell cultures of parental H460 cells and DSCs, imaged on indicated day of culture. B, Maintenance of enhanced ability to form tumor spheres during
several generations of DSCs transfer (for comparison only 1-st and 5-th generation’s data are presented). C, Immunofluorescent images of lung tumor
spheres stained for CD133, CD117 and TRA-1-81 (10X objective).
doi:10.1371/journal.pone.0003077.g005
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with 56104 cells, and it required an injection of 56105 H460
tumor cells to develop tumors in 100% of SCID mice. Thus, DSCs
demonstrated a substantially higher tumorigenic ability than H460
cells. Moreover, all tumors that developed from DSCs grew faster
than those developed from parental cells as assessed by the time
required for mice to bear tumors of 2000 mm3. All mice bearing
DSC-derived tumors were sacrificed 2 wk earlier than animals
inoculated with parental H460 cells. Tumor samples were frozen
and used subsequently for cytokine analysis.
DSCs show high metastatic capacity
We suggested that pulmonary metastasis formation following
i.v. inoculation of tumor cells may be more indicative of the CSC
nature of the DSCs lung tumor cells than subcutaneous
tumorigenicity. It considered that metastatic nodules can originate
from a single cell [38]. Therefore, the ability to form experimental
metastases growing under orthotopic conditions in the lungs could
be an ideal test for lung CSCs malignant potential. To compare
metastatic ability, 56104 H460 cells and 56104 DSCs were
inoculated i.v. into SCID mice. Sixty days after inoculation,
metastatic nodules were found only in the lungs. It was also
Figure 6. In vitro differentiation potential of lung cancer sphere cells and drug resistance of CSCs. A, Loss of stem cell marker (CD133)
and increase of differentiation markers (CK8/18) by lung CSCs differentiated progenitors. Parental H460 cells and CSCs from tumor spheres were seeded
in collagen coated well plates and cultured for 3 weeks in complete RPMI 1640 medium supplemented with 10% FBS. Upper row - cell images in
phase –contrast microscopy; in the middle - cells immunofluorescently stained for CD133 and bottom row - cells immunofluorescently stained for CK
8/18. B, Self-renewing ability of differentiated lung cancer cells treated with cisplatin. Relative % of cells generated tumor spheres from single-cell
suspension cultures of drug selected CSCs, cells differentiated during 3 weeks and Progenitors of CSCs differentiated for 3 weeks were treated with
cisplatin (1 mM) for two days. Surviving cells were transferred into low adherent plates and cultured in semisolid serum free medium supplemented
with growth factors. Numbers of formed tumor spheres were determined and presented as percent of control. Control is number of spheres formed
by transfer of cells derived from control tumor spheres. Number of these spheres is accepted as 100 %. C, Effect of cisplatin and doxorubicin on
proliferation of parental H460 cells, CSCs and their differentiated cells. H460, lung CSCs and differentiated cells were plated in 96-well plates precoated
with Collagen at 16104 cells/well in complete RPMI 1640 medium with 10% FBS. After 24 h doxorubicin or cisplatin was added at the indicated
concentrations. Cells were cultured for 72 h, fixed, stained with Hoechst 33342 (2 mg/mL), and counted using the Cellomics ArrayScan HCS Reader.
doi:10.1371/journal.pone.0003077.g006
Table 1. Tumorigenic and metastatic properties of H460 cells
and lung CSCs.
Subcutaneous tumors in SCID mice*




Median No. of experimental pulmonary metastases (metastases in
individual mouse)**
No. of tumor cells inoculated H460 CSCs
56104 0 (0,0,0,1,3) 58 (36, 47, 58, 173, 194)
*H460 cells and CSCs were injected s.c. into SCID mice at concentrations of
56103–56105 cells (in 200 ml PBS) per mouse. Mice were sacrificed when
tumors reach 2 cm in diameter.
**H460 cells and CSCs were inoculated i.v. into the tail vein of SCID mice (56104
tumor cells/mouse). After 60 days mice were sacrificed, lungs were removed
and fixed in the Bouin’s solution, and metastatic nodules were counted under
a dissecting microscope.
doi:10.1371/journal.pone.0003077.t001
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observed that parental H460 cells and DSCs differed dramatically
in their capacity to develop lung metastases in SCID mice
(Table 1). Whereas inoculated DSCs gave rise to multiple
pulmonary metastases in all five animals (total of 508 metastases),
inoculation with parental H460 cells resulted in the development
of metastatic nodules in only two of five mice, with one and three
metastatic nodules in each mouse. Thus, these results in
combination with all in vitro experiments indicate that DSCs
have all characteristics of CSCs. Hereafter DSCs will be termed
CSCs.
H460 cells and CSCs grown in SCID mice differ in
cytokine production
The mechanisms responsible for the high tumorigenic and
metastatic ability of CSCs remain unclear. We hypothesize that
high tumorigenicity and metastastatic ability of CSCs are
associated with their high ability to produce growth and
angiogenic factors. These factors, through autocrine and paracrine
mechanisms, support the proliferation of tumor cells and stimulate
blood vessel formation that provide oxygen and nutrients essential
for tumor growth. To test this, we analyzed various cytokines,
chemokines, and angiogenic and growth factors in the lysates of
H460- and CSC-derived tumors grown in SCID mice. Human
tumors growing in SCID mice consist of human cells and murine
stroma. This provides a unique opportunity to differentially
analyze cytokines produced by human tumor cells and by murine
stromal cells. For such analysis, we prepared sonicated lysates of
tumors grown subcutaneously in SCID mice after inoculation of
56105 parental H460 cells or CSCs. Analysis of human cell-
produced factors was performed using multiplex kits and Luminex
technology for the detection of human proteins as described in
Materials and Methods. The analysis revealed that human tumor
cells growing in vivo produced a broad spectrum of cytokines and
growth factors. Many factors were similarly produced by H460
and CSCs, such as IL-1b, IL-7, IL-10, IL-12p40, IL-15, MCP-2,
RANTES, EOTAXIN, MIP-1b, IP-10, GROa, Fractalkine,
sFAS, M-CSF, IL-1Ra, IL-2R, sIL-6R, and ErbB2. Nineteen
different growth factors, cytokines, and chemokines were found to
be substantially higher in the lysates of CSCs than in lysates of
H460 tumors (Table 2). The levels of growth and proangiogenic
factors VEGF, bFGF, IL-8, IL-6, HGF, PDGF-BB, G-CSF and
IGFBP-1 were 2–3 folds higher in CSC tumors than in H460-
derived tumors (Table 2).
The most remarkable differences were in the levels of stem cell
growth factor-b (SCGF-b) in CSC-derived tumor lysates as
compared to H460-derived tumor lysates. In addition, increased
levels of stroma-derived factor-1a (SDF-1a) and stem cell factor
(SCF) were found in lysates of CSC-derived tumors (Table 2).
CSCs also produced significantly higher levels of chemokines
(MIP-1a, MCP-1, and MIG), as well as INFa, TRAIL, and TNF-
a (Table 2).
Taken together, these data demonstrate that high tumorigenic
and metastatic potentials of CSCs correlate with superior
production of angiogenic and growth factors involved in cell
proliferation and angiogenesis. Increased levels of SCGF-b, SDF-
1a, and SCF in tumors from CSCs are indicative of their stem cell
origin.
H460 and CSCs cells cultured in vitro also showed differences in
cytokine secretion. Lung CSCs produced twenty-fold more bFGF
than H460 cells (Figure 7A). They also secreted higher levels of
Table 2. Multiplex analysis of cytokines and growth factors in the lysates of xenografted parental H460 and CSC-derived tumors.
Tumor Producing Factors Mean6SE pg/mg of protein
Cytokines H460-derived tumor CSCs-derived tumor P value
1 IGFBP-1 18,85361,583 62,09066,210 ,0.001
2 VEGF 3,2186516 8,2496980 ,0.001
3 IL-8 6,2956905 10,3606700 ,0.05
4 IL-6 1,8086184 3,5996479 ,0.05
5 bFGF 941684 3,0556657 ,0.01
6 HGF 183624 413631 ,0.001
7 PDGF-BB 861 2466 ,0.05
8 SCGF-b 10156149 16,59964,802 ,0.001
9 SDF-1a 197638 895685 ,0.05
10 SCF 6164 8061 ,0.05
11 G-CSF 1561 344622 ,0.001
12 GM-CSF 1362 2864 ,0.01
13 IFNa2 94613 203627 ,0.05
14 MIP-1a 1861 3865 ,0.01
15 MCP-1 660.5 1562 ,0.01
16 MIG 860.8 1661 ,0.05
17 PAI-1 459625 1,5466142 ,0.01
18 TNFa 4869 9469 ,0.05
19 TRAIL 116623 231623 ,0.05
Sonicated extracts were prepared from H460- and CSC-derived tumors growing in SCID mice (5 tumors per group) and concentrations of various tumor-producing
cytokines, chemokines, angiogenic and growth factors were analyzed using multiplex kits. Only factors with significant differences in their concentrations (at least
p,0.05) are included.
doi:10.1371/journal.pone.0003077.t002
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VEGF, IL-6, SCGF-b, and alpha-fetoprotein (AFP) than H460
cells (Figure 7A). In general, the spectrum of factors produced by
these cells in vivo was much broader than those in vitro. This
observation could be attributed to in vivo conditions being more
conducive to the functional activity of tumor cells and their ability
to produce various factors required for tumor growth.
Analysis of MMPs and adhesion molecules in tumor
samples
MMPs and adhesion molecules play a critical role in tumor
invasion and metastasis [39,40]. We analyzed the levels of three
MMPs in the lysates of H460 and CSC tumors. Higher amounts of
MMP-2 and MMP-3 were found in CSC-derived tumors than in
H460 cell-derived tumors (Table 3), whereas no differences in
expression of MMP-9 were observed. Higher levels of intercellular
cell adhesion molecule-1 (ICAM-1) and vascular endothelial cell
adhesion molecule-1 (VCAM-1) were detected in CSC-derived
tumors. In addition, CSC-derived tumors contained higher levels
of CYFRA 21-1 and mesothelin (Table 3), well-known lung tumor
markers [41,42].
Analysis of cancer antigens
Many cancer-associated antigens are encoded by genes
normally expressed in germ cells, trophoblasts, and embryonic
cells [43]. We hypothesized that CSCs may express higher levels of
embryonic antigens. To test this hypothesis, an analysis of
serologically detectable cancer antigens (AFP, CEA, CA-125,
CA 19-9, CA 15-3, and CA72-4) in the CSC- and H460-derived
tumors was performed. Carcinoembryonic antigen (CEA) was the
most prevalent cancer antigen in the tested tumor lysates
regardless of origin; however, CSC-derived tumors contained
three-fold higher CEA concentrations than parental H460-derived
tumors (Table 3). The levels of AFP and CA 125 were almost two
fold higher in CSC-derived tumors than in H460 tumors. The
most dramatic difference was found in CA 72-4. The level of CA
72-4 detected in lysates of H460 cells was 5 pg/mg, whereas in
CSCs tumors it reached 310 pg/mg of protein (Table 3). These
data indicate that CSCs growing in vivo express higher levels of
embryonic cancer antigens (CEA and AFP) as well as CA 125 and
CA 72-4 when compared with parental cells.
Mouse stroma-derived cytokines in human tumor
xenografts
To measure cytokines produced by host stroma, multiplex kits
for detection of 19 murine cytokines were used. Most factors were
present in mouse tumor stroma at low or undetectable
concentrations; however, levels of mouse proangiogenetic cyto-
kines VEGF, bFGF, MCP-1, and MIP-1a in CSC-derived tumor
samples were significantly higher than those in parental H460
extracts (Figure 7B). These results indicate that CSCs stimulate
stroma formation more effectively than H460 cells. Of note, SCID
mice lack T, B, and NKT cells, and thus stroma of xenografted
human tumor is deficient in these and probably other inflamma-
tory cells (macrophages, dendritic cells, neutrophils) that could
contribute to a pool of stromal cytokines and chemokines.
Taken together, the comparative analysis of human factors
produced in vivo and in vitro by CSCs and H460 cells show multiple
differences in the range and amount of cytokines, thus highlighting
the advantage of CSCs in proinflammatory niche formation and
metastatic ability. Cytokines and growth factors exert their
functions by binding to their respective receptors. Therefore, next
we compared expression of growth and angiogenetic factors
receptors in parental H460 cells and lung CSCs growing in
adherent condition and in tumor spheres.
Increased expression of growth factor and chemokine
receptors by CSCs
Lung CSCs produced three-fold increased levels of VEGF
(Table 2), a potent angiogenic factor which stimulates migration
and proliferation of endothelial cells and formation of blood vessels
by binding to its cognate receptors. Some evidence indicates that
VEGF receptors (VEGFR1 and VEGFR2) are also expressed by
tumor cells to facilitate pro-survival signaling that protects these
cells from drug-induced apoptosis and stimulates their prolifera-
tion [44].
We used ArrayScanHVTI HCS Reader (Cellomics Inc) to
identify VEGFR1 and VEGFR2 receptor expression in parental
H460 cells and lung CSCs cultured under adherent conditions for
8 h. Both H460 parental tumor cells and CSCs expressed
VEGFR1 (Figure 8A). However, lung CSCs showed higher levels
of VEGFR1 expression than parental H460 cells (Figure 8B). The
immunostaining of entire tumor spheres revealed high levels of
VEGFR1 expression by CSCs (Figure 10C). VEGFR2 receptor
was undetectable in analyzed cells.
FGF-b is an essential stemness supporting growth factor for both
embryonic and cancer stem cells [45]. Additionally, it is a potent
regulator of angiogenesis [46]. As we have shown above, lung
CSCs produced an elevated level of bFGF both in vivo and vitro
Figure 7. Multiplex analysis of cytokines. A, In vitro cytokine
production by CSCs and parental human tumor H460 cells. Cells were
cultivated in 96-well plates for 24 h in complete RPMI 1640 medium;
samples of conditioned media were collected. Cells were fixed, stained
with Hoechst 33342, and cell numbers were determined using image
cytometry. Concentrations of human cytokines, chemokines, growth
factors, MMPs, adhesion molecules and cancer antigens were analyzed
using Luminex technology. Concentrations of cytokines pg/106 cells/ml
were calculated. Only factors with significant differences in their
concentrations are presented. B, Analysis of murine cytokines in extracts
of xenografted parental H460 and CSCs-derived tumors. SCID mice were
inoculated s.c with 56105 of parental H460 or CSCs (5 mice per group).
Samples of tumors, derived from parental H460 cells and CSCs, were
sonicated, and concentrations of 19 murine cytokines in cellular extracts
were measured using multiplexed cytokine assays as described in
Materials and Methods. Only factors with significant differences in their
concentrations (at least p,0.05) are included. Results are presented as
pg or ng of cytokine per mg of total tumor protein.
doi:10.1371/journal.pone.0003077.g007
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Table 3. Multiplex analysis of adhesive molecules, MMPs and cancer antigens in the lysates of xenografted parental H460 and
CSC-derived tumors.
Tumor Producing Factors Mean6SE pg/mg of protein
Receptors, adhesive and other molecules H460-derived tumor CSCs-derived tumor P value
1 DR-5 589643 783640 ,0.01
2 TNF-R1 162623 546670 ,0.001
3 VCAM-1 2,1906112 3,9226604 ,0.01
5 ICAM-1 137,20767,385 185,007612,176 ,0.05
5 Mesothelin 54,61763,956 106,625617,695 ,0.01
6 Cyfra 21-1 84,57764,367 173,025620.963 ,0.01
MMPs Mean6SE pg/mg of protein
7 MMP-3 undetectable 8163 ,0.001
8 MMP-2 8,1296250 9,7676560 ,0.05
Cancer Antigens Mean6SE pg/mg of protein
9 CEA 10,7466523 31,18963,364 ,0.05
10 AFP 1462.7 2562.8 ,0.05
11 CA 125 2863.6 4363.7 ,0.05
12 CA 72-4 561.9 310648 ,0.001
Sonicated extracts were prepared from H460- and CSC-derived tumors growing in SCID mice (5 tumors per group) and concentrations of various tumor-producing
factors were analyzed using multiplex kits. Only factors with significant differences in their concentrations (at least p,0.05) are included.
doi:10.1371/journal.pone.0003077.t003
Figure 8. Increased expression of growth factor receptors (VEGFR1, FGFR2,) in lung CSCs. H460 cells and lung CSCs dissociated from
spheres were plated into 96-well plates precoated with Collagen IV and cultured 8 h. Then adherent cells were incubated with FITC-conjugated Abs
against FGFR2, VEGFR1 and VEGFR2 fixed and stained with Hoechst 33342. Images were acquired using the Cellomics ArrayScan HCS Reader (20X
objective) and analyzed using the Target Activation BioApplication Software Module. A, Immunofluorescent images of VEGFR1 and FGFR2 in H460 and
CSCs cells (20X objective). B, Fluorescence intensity (pix) of VEGFR1 and FGFR2 plotted against object area. Each point represents a single cell. In figures 8–
10 red lines show the boundaries of the fluorescence intensity of H460 cells.
doi:10.1371/journal.pone.0003077.g008
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(Table 2, Figure 7A). We therefore expected that lung CSCs would
express elevated levels of bFGF receptors as well. Indeed,
expression of FGFR2 was elevated in lung CSCs growing in
adherent conditions (Figure 8).
IL-8 (CXCL8) is well known multifunctional prosurvival and
proinflammatory chemokine involved in tumorigenesis, angiogen-
esis, and metastasis formation [47]. Lung CSCs exhibited higher
levels of IL-8 in vivo (Table 2) and in vitro (Figure 7A). We also
found that lung CSCs express high levels of IL-8 receptors,
CXCR1, and CXCR2 (Figure 9, 10) as well as FGFR2 in tumor
spheres Figure 10).
Stromal derived factor-1 (SDF-1, CXCL12) and its receptor,
CXCR4, were significantly elevated in lung CSCs when compared
with parental H460 cells (Table 2, Figure 10).
Our results clearly show that lung CSCs are characterized by
higher production of growth and angiogenetic factors as well as
higher expression of their receptors. These upregulations in
cytokine network could serve as the basis for the enhanced
tumorigenic and metastatic potentials of lung CSCs.
Discussion
Our findings demonstrate that CSCs are resistant to chemother-
apeutic drugs and can be selected from the parental population of
human H460 lung tumor cells by treatment with drugs. Cells, which
survived drug treatment, have all the properties of CSCs. Indeed,
DSCs had high clonogenic efficiency, were enriched in SP
phenotype, and expressed markers associated with CSCs, such as
CD133. Expression of CD133 was found in CSCs of several
different cancers, including brain, prostate, and pancreatic
[2,4,7,8]. Recently CD133+ lung CSCs were identified as well
[10]. In our study we have shown that DSCs express putative
embryonic markers Oct-4, SSEA-3, and TRA1-81 [6,48,49] and
exhibit nuclear accumulation of b-catenin, which is believed to be a
key event in stem cell activation [32–34,50]. In parallel with
expression of the phenotypic markers associated with CSCs, DSCs
express low levels of epithelial differentiation markers (cytokeratins
8/18), further confirming the undifferentiated status of these cells.
Self-renewal and the ability to generate differentiated progen-
itors are considered fundamental properties of CSCs [1,17]. We
found that DSCs, in contrast to parental H460 cells, have a high
ability to generate and maintain tumor spheres for numerous
generations in selective culture conditions, indicating their high
self-renewal potential. Furthermore, DCSs were able to differen-
tiate and generate progenitors that acquired the differentiation
markers cytokeratins 8/18 with parallel loss of CD133 and ability
to form spheres. It is interesting that these differentiated tumor
cells also acquired drug sensitivity, the vast majority of these cells
were killed with cisplatin, and a small proportion of surviving cells
maintained the ability to form spheres. Drugs did not avert CSC
proliferation, but could prevent their differentiation, helping to
preserve enrichment for CSCs in the population.
Finding that lung CSCs are resistant to different drugs (cisplatin,
doxorubicin and etoposide) suggests the involvement of the
Figure 9. Increased expression of chemokine receptors (CXCR1, 2) in lung CSCs. A, Immunofluorescent images of CXCR1 and CXCR2 in H460
and CS cells. H460 cells and lung CSCs dissociated from spheres were plated into 96-well plates precoated with Collagen IV and cultured 8 h. Then
adherent cells were incubated with antibodies against CXCR1 and CXCR2 and with secondary antibodies conjugated with Alexa FluorH 488 and
stained with Hoechst33342. Images were acquired using the Cellomics ArrayScan HCS Reader (20X objective) and analyzed using the Target
Activation BioApplication Software Module. B, Fluorescence intensity (pix) of CXCR1 and CXCR2 plotted against object area.
doi:10.1371/journal.pone.0003077.g009
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complex mechanisms in their drug resistance that require further
investigation. It is intriguing that changes during differentiation
lead to the drug sensitivity of their differentiated progenitors.
The presence of CSCs in tumor cell lines propagated in vitro for
many years put forth the idea that CSCs may be important for the
maintenance of the tumor cell population not only in vivo but also
in vitro. Elimination of drug sensitive differentiated tumor cells and
enrichment of CSCs following drug treatment observed in our in
vitro model of human lung cancer suggest that similar selection of
drug resistant CSCs could be observed in clinical practice during
chemotherapy. Recently it was reported that breast tumors from
patients treated with chemotherapy contained higher proportion
of CD44+, CD24low cells with CSC properties than breast tumors
from untreated patients [20].
High tumorigenic potential is a hallmark of CSCs. We found
that DSCs, in comparison to parental H460 cells, have higher
tumorigenic potential following s.c. inoculation into SCID mice. It
has also been suggested that CSCs have high metastatic potential
and can initiate the formation of distant metastases [21], although
direct confirmation of this possibility still absent. It is widely held
that metastatic tumors can develop from a single tumor cell. The
metastatic process is highly selective and requires a tumor cell to
survive during hematogenic spread and extravasation, followed by
the development of supporting stroma and proliferation in distant
tissues and organs [38]. We found that following i.v. inoculation of
low amounts (56104) of tumor cells into SCID mice, DSCs formed
numerous metastatic tumors in the lungs, whereas parental H460
cells failed to form any metastases in the majority of mice.
Thus, our in vitro and in vivo experiments demonstrate that DSCs
possess all known characteristics of CSCs. What remains
unknown; however, are the precise mechanisms by which CSCs
are highly tumorigenic and metastatic. We found increased levels
of adhesion molecules (VLA-5, ICAM-1, and VCAM-1) as well as
MMP2 and MMP3 that could be contributing factors to the
metastatic potential of CSCs. Recently it was shown that the
CD133+ CXCR4+ pancreatic CSC population is the only cell
population responsible for tumor metastasis in pancreatic cancer
[8]. This finding appears to agree with our own in which lung
CSCs isolated by drug treatment were CD133+ with increased
levels of CXCR4 expression.
The high tumorigenic and metastatic properties of CSCs could
be based on their increased ability to produce cytokines,
chemokines, and angiogenic and growth factors, which, through
autocrine and paracrine mechanisms, stimulate proliferation of
tumor cells and migration and proliferation of stromal cells to form
of a network of blood vessels that support tumor growth. We
performed a comprehensive analysis of these factors in sonicated
lysates of xenografted tumors derived from parental H460 cells
and CSCs. We found that CSCs, in comparison with H460 tumor
cells, produced up to two to threefold higher level of angiogenic
and growth factors (VEGF, PDGF-BB, bFGF, IGFBP-b, and
HGF). Moreover, lung CSCs showed higher levels of VEGFR1
Figure 10. Expression of growth factor and chemokine receptors in lung CSCs. A, B, H460 cells and lung CSCs dissociated from spheres
were plated into 96-well plates precoated with Collagen IV and cultured 8 h. Then adherent cells were immunofluorescently stained for CXCR4 (SDF-1
receptor); images were acquired using the Cellomics ArrayScan HCS Reader (20X objective) and analyzed using the Target Activation BioApplication
Software Module. A. Immunofluorescent images of CXCR4 in H460 and CSCs cells. B. Fluorescence intensity (pix) of CXCR4 is plotted against object area. C.
Expression of growth factor and chemokine receptors in lung CSCs growing in tumor spheres. Lung tumor spheres were immunofluorescently stained for
VEGFR1; FGFR2, CXCR1 and CXCR4 receptors; images were acquired using the Cellomics ArrayScan HCS Reader (10X objective). Immunofluorescent
images of lung tumor spheres stained for VEGFR1, FGFR2, CXCR1 and CXCR4 are presented.
doi:10.1371/journal.pone.0003077.g010
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and FGFR2 receptors. FGFb is a known fundamental growth
factor, supporting the maintenance of embryonic stem cell and
CSC populations [45]. Remarkably, CSC tumor lysates contained
a very high level of SCGF-b and increased levels of SCF and SDF-
1 – cytokines associated with the stem cell phenotype [51–53].
CSC-derived tumors have elevated levels of G-CSF and GM-CSF,
which stimulate proliferation and differentiation of bone marrow
cells and play a role in endothelial progenitor cell mobilization and
proliferation via activation of STAT3 and STAT5 and upregula-
tion of VEGF and its receptor, VEGFR2 [54].
CSC-derived tumors contain increased levels of proinflamma-
tory cytokine IL-6 and chemokines IL-8 (CXCL8), MCP-1
(CCL2), and MIP-1a (CCL15), which are potent stimulators of
angiogenesis and tumor cell proliferation and play an important
role in tumor progression and metastasis in a variety of human
cancers, including lung cancers [33]. In addition, we observed
increased expression of both IL-8 receptors, CXCR1 and
CXCR2, in lung CSCs. The chemokines and growth factors
produced by the tumor by binding to the cognate receptors on
tumor and stroma cells could provide proliferative and anti-
apoptotic signals helping the tumor cells escape drug-mediated
destruction. Indeed, we recently demonstrated that supernatants
conditioned by tumor cells stimulate tumor cell proliferation and
increase their resistance to chemotherapeutic drugs. Antibodies
that neutralized tumor cell produced chemokines increased their
sensitivity to drugs [55].
Human tumors growing in SCID mice consist of human cells
and murine stroma. Multiplex analysis of murine cytokines and
growth factors revealed an increased level of murine angiogenic
factors VEGF, bFGF, as well as MIP-1a and MCP-1 in CSCs-
derived tumors in comparison to parental H460 tumors growing in
SCID mice, indicating that CSCs more efficiently stimulate
murine proangiogenic factors and blood vessel formation to
support the growth of xenografted human tumor.
Drug resistance of CSCs represents a serious obstacle for current
chemotherapy-based treatment strategies, for which alternative
approaches must be considered [56]. It is possible that CSCs might
serve as a target for immunotherapy. Some cancer-associated
antigens represent embryonic antigens that are predominantly
expressed during embryonic development and completely or
partially absent afterward. However, these antigens are often
detected in malignantly transformed cells [43]. A substantial
increase of embryonic antigens AFP and CEA was detected in
CSC-derived tumors. Although the biological significance of these
antigens remains unclear, it was recently reported that CEA inhibits
anoikis by binding to TRAIL receptor DR-5 and preventing
apoptotic signaling in tumor cells [57]. Our findings that that lung
CSCs overexpressed CEA, DR5, and its ligand TRAIL provide
strong support for this argument. In addition to AFP and CEA,
CSC-derived tumors contained increased levels of CA 125 and CA
72-4, which are considered biomarkers of lung cancer [58] and
provide additional target for immunotherapy.
Clinically, chemotherapy is typically administered in several
cycles separated by three-week intervals in order to allow the body
to restore hematopoietic and other normal cells damaged by
drugs. However, some reports indicate that during this resting
period tumor cells can aggressively repopulate the tumor and
restore pre-treatment tumor size [59]. Based on our experimental
data, it is plausible to conclude that chemotherapy increases the
proportion of CSCs by elimination of drug sensitive differentiated
tumor cells that could be restored during three weeks of rested
period. Our data indicate that although differentiated tumor cells
gain drug sensitivity, their populations keep higher proportion of
CSCs and manifest higher drug resistance than original cell
populations. With several cycles of chemotherapy the proportion
of drug resistant CSCs or their early progenitors could further
increase making the whole tumor even more resistant with each
cycle of chemotherapy.
Further characterization of lung CSCs and the mechanisms of
their drug resistance, as well as an investigation of their complex
cytokine network, may provide key information on relevant
pathways to be targeted to increase the therapeutic response.
Acknowledgments
We thank Hongmei Shen for MoFlo cell sorting; Brian Nolen for the
critical review of the manuscript; Ligita Griniene, Xiaojun Huang, and
Liudmilla Velikokhatnaya for the technical support.
Author Contributions
Conceived and designed the experiments: VL EG. Performed the
experiments: VL AMM. Analyzed the data: VL RD. Contributed
reagents/materials/analysis tools: EG AEL. Wrote the paper: VL EG
AEL.
References
1. Reya T, Morrison SJ, Clarke MF, Weissman IL (2001) Stem cells, cancer, and
cancer stem cells. Nature 414: 105–111.
2. Vescovi AL, Galli R, Reynolds BA (2006) Brain tumour stem cells. Nat Rev
Cancer 6: 425–436.
3. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF (2003)
Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad
Sci U S A 100: 3983–3988.
4. Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, et al. (2004)
Identification of human brain tumour initiating cells. Nature 432: 396–401.
5. Collins AT, Maitland NJ (2006) Prostate cancer stem cells. Eur J Cancer 42:
1213–1218.
6. Adewumi O, Aflatoonian B, Ahrlund-Richter L, Amit M, Andrews PW, et al.
(2007) Characterization of human embryonic stem cell lines by the International
Stem Cell Initiative. Nat Biotechnol 25: 803–816.
7. Miki J, Furusato B, Li H, Gu Y, Takahashi H, et al. (2007) Identification of
putative stem cell markers, CD133 and CXCR4, in hTERT-immortalized
primary nonmalignant and malignant tumor-derived human prostate
epithelial cell lines and in prostate cancer specimens. Cancer Res 67:
3153–3161.
8. Hermann PC, Huber SL, Herrler T, Aicher A, Ellwart JW, et al. (2007) Distinct
populations of cancer stem cells determine tumor growth and metastatic activity
in human pancreatic cancer. Cell Stem Cell 1: 313–323.
9. Ricci-Vitiani L, Lombardi DG, Pilozzi E, Biffoni M, Todaro M, et al. (2007)
Identification and expansion of human colon-cancer-initiating cells. Nature 445:
111–115.
10. Eramo A, Lotti F, Sette G, Pilozzi E, Biffoni M, et al. (2008) Identification and
expansion of the tumorigenic lung cancer stem cell population. Cell Death Differ
15: 504–514.
11. Todaro M, Perez Alea M, Scopelliti A, Medema JP, Stassi G (2008) IL-4-
mediated drug resistance in colon cancer stem cells. Cell Cycle 7: 309–313.
12. Goodell MA, Brose K, Paradis G, Conner AS, Mulligan RC (1996) Isolation and
functional properties of murine hematopoietic stem cells that are replicating in
vivo. J Exp Med 183: 1797–1806.
13. Zhou S, Schuetz JD, Bunting KD, Colapietro AM, Sampath J, et al. (2001) The
ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells and
is a molecular determinant of the side-population phenotype. Nat Med 7:
1028–1034.
14. Szotek PP, Pieretti-Vanmarcke R, Masiakos PT, Dinulescu DM, Connolly D, et
al. (2006) Ovarian cancer side population defines cells with stem cell-like
characteristics and Mullerian Inhibiting Substance responsiveness. Proc Natl
Acad Sci U S A 103: 11154–11159.
15. Ho MM, Ng AV, Lam S, Hung JY (2007) Side population in human lung cancer
cell lines and tumors is enriched with stem-like cancer cells. Cancer Res 67:
4827–4833.
16. Ignatova TN, Kukekov VG, Laywell ED, Suslov ON, Vrionis FD, et al. (2002)
Human cortical glial tumors contain neural stem-like cells expressing astroglial
and neuronal markers in vitro. Glia 39: 193–206.
17. Dontu G, Abdallah WM, Foley JM, Jackson KW, Clarke MF, et al. (2003) In
vitro propagation and transcriptional profiling of human mammary stem/
progenitor cells. Genes Dev 17: 1253–1270.
Lung CSCs and Cytokine Network
PLoS ONE | www.plosone.org 15 August 2008 | Volume 3 | Issue 8 | e3077
18. Farnie G, Clarke RB (2007) Mammary stem cells and breast cancer--role of
Notch signalling. Stem Cell Rev 3: 169–175.
19. Dean M, Fojo T, Bates S (2005) Tumour stem cells and drug resistance. Nat Rev
Cancer 5: 275–284.
20. Yu F, Yao H, Zhu P, Zhang X, Pan Q, et al. (2007) let-7 regulates self renewal
and tumorigenicity of breast cancer cells. Cell 131: 1109–1123.
21. Li F, Tiede B, Massague J, Kang Y (2007) Beyond tumorigenesis: cancer stem
cells in metastasis. Cell Res 17: 3–14.
22. Ferrara N, Alitalo K (1999) Clinical applications of angiogenic growth factors
and their inhibitors. Nat Med 5: 1359–1364.
23. Bouck N, Stellmach V, Hsu SC (1996) How tumors become angiogenic. Adv
Cancer Res 69: 135–174.
24. Strieter RM, Belperio JA, Burdick MD, Sharma S, Dubinett SM, et al. (2004)
CXC chemokines: angiogenesis, immunoangiostasis, and metastases in lung
cancer. Ann N Y Acad Sci 1028: 351–360.
25. Petreaca ML, Yao M, Liu Y, Defea K, Martins-Green M (2007) Transactivation
of vascular endothelial growth factor receptor-2 by interleukin-8 (IL-8/CXCL8)
is required for IL-8/CXCL8-induced endothelial permeability. Mol Biol Cell 18:
5014–5023.
26. Ferrara N, Hillan KJ, Novotny W (2005) Bevacizumab (Avastin), a humanized
anti-VEGF monoclonal antibody for cancer therapy. Biochem Biophys Res
Commun 333: 328–335.
27. Levina V, Marrangoni AM, Demarco R, Gorelik E, Lokshin AE (2008) Multiple
effects of TRAIL in human carcinoma cells: Induction of apoptosis, senescence,
proliferation, and cytokine production. Exp Cell Res 314: 1605–1616.
28. Gorelik E, Wiltrout RH, Okumura K, Habu S, Herberman RB (1982) Role of
NK cells in the control of metastatic spread and growth of tumor cells in mice.
Int J Cancer 30: 107–112.
29. Gorelik E, Landsittel DP, Marrangoni AM, Modugno F, Velikokhatnaya L, et
al. (2005) Multiplexed immunobead-based cytokine profiling for early detection
of ovarian cancer. Cancer Epidemiol Biomarkers Prev 14: 981–987.
30. Roninson IB (2003) Tumor cell senescence in cancer treatment. Cancer Res 63:
2705–2715.
31. Kanaji N, Bandoh S, Fujita J, Ishii T, Ishida T, et al. (2007) Compensation of
type I and type II cytokeratin pools in lung cancer. Lung Cancer 55: 295–302.
32. Reya T, Clevers H (2005) Wnt signalling in stem cells and cancer. Nature 434:
843–850.
33. Aggarwal BB, Shishodia S, Sandur SK, Pandey MK, Sethi G (2006)
Inflammation and cancer: how hot is the link? Biochem Pharmacol 72:
1605–1621.
34. Fodde R, Brabletz T (2007) Wnt/beta-catenin signaling in cancer stemness and
malignant behavior. Curr Opin Cell Biol 19: 150–158.
35. Ridley AJ, Schwartz MA, Burridge K, Firtel RA, Ginsberg MH, et al. (2003)
Cell migration: integrating signals from front to back. Science 302: 1704–1709.
36. Zhu Z, Sanchez-Sweatman O, Huang X, Wiltrout R, Khokha R, et al. (2001)
Anoikis and metastatic potential of cloudman S91 melanoma cells. Cancer Res
61: 1707–1716.
37. Ponti D, Costa A, Zaffaroni N, Pratesi G, Petrangolini G, et al. (2005) Isolation
and in vitro propagation of tumorigenic breast cancer cells with stem/progenitor
cell properties. Cancer Res 65: 5506–5511.
38. Fidler IJ, Hart IR (1982) Biological diversity in metastatic neoplasms: origins and
implications. Science 217: 998–1003.
39. Westermarck J, Kahari VM (1999) Regulation of matrix metalloproteinase
expression in tumor invasion. Faseb J 13: 781–792.
40. Coussens LM, Fingleton B, Matrisian LM (2002) Matrix metalloproteinase
inhibitors and cancer: trials and tribulations. Science 295: 2387–2392.
41. Buccheri G, Ferrigno D (2001) Lung tumor markers of cytokeratin origin: an
overview. Lung Cancer 34 Suppl 2: S65–69.
42. Hassan R, Remaley AT, Sampson ML, Zhang J, Cox DD, et al. (2006)
Detection and quantitation of serum mesothelin, a tumor marker for patients
with mesothelioma and ovarian cancer. Clin Cancer Res 12: 447–453.
43. Simpson AJ, Caballero OL, Jungbluth A, Chen YT, Old LJ (2005) Cancer/testis
antigens, gametogenesis and cancer. Nat Rev Cancer 5: 615–625.
44. Rosen LS (2001) Angiogenesis inhibition in solid tumors. Cancer J 7 Suppl 3:
S120–128.
45. Fang D, Nguyen TK, Leishear K, Finko R, Kulp AN, et al. (2005) A
tumorigenic subpopulation with stem cell properties in melanomas. Cancer Res
65: 9328–9337.
46. Almeida GM, Duarte TL, Farmer PB, Steward WP, Jones GD (2008) Multiple
end-point analysis reveals cisplatin damage tolerance to be a chemoresistance
mechanism in a NSCLC model: implications for predictive testing. Int J Cancer
122: 1810–1819.
47. Bar-Eli M (1999) Role of interleukin-8 in tumor growth and metastasis of human
melanoma. Pathobiology 67: 12–18.
48. Matin MM, Walsh JR, Gokhale PJ, Draper JS, Bahrami AR, et al. (2004)
Specific knockdown of Oct4 and beta2-microglobulin expression by RNA
interference in human embryonic stem cells and embryonic carcinoma cells.
Stem Cells 22: 659–668.
49. Schopperle WM, DeWolf WC (2007) The TRA-1-60 and TRA-1-81 human
pluripotent stem cell markers are expressed on podocalyxin in embryonal
carcinoma. Stem Cells 25: 723–730.
50. Malanchi I, Peinado H, Kassen D, Hussenet T, Metzger D, et al. (2008)
Cutaneous cancer stem cell maintenance is dependent on beta-catenin
signalling. Nature 452: 650–653.
51. Gabrilove JL, White K, Rahman Z, Wilson EL (1994) Stem cell factor and basic
fibroblast growth factor are synergistic in augmenting committed myeloid
progenitor cell growth. Blood 83: 907–910.
52. Peled A, Kollet O, Ponomaryov T, Petit I, Franitza S, et al. (2000) The
chemokine SDF-1 activates the integrins LFA-1, VLA-4, and VLA-5 on
immature human CD34(+) cells: role in transendothelial/stromal migration and
engraftment of NOD/SCID mice. Blood 95: 3289–3296.
53. Kortesidis A, Zannettino A, Isenmann S, Shi S, Lapidot T, et al. (2005) Stromal-
derived factor-1 promotes the growth, survival, and development of human bone
marrow stromal stem cells. Blood 105: 3793–3801.
54. Morales-Arias J, Meyers PA, Bolontrade MF, Rodriguez N, Zhou Z, et al. (2007)
Expression of granulocyte-colony-stimulating factor and its receptor in human
Ewing sarcoma cells and patient tumor specimens: potential consequences of
granulocyte-colony-stimulating factor administration. Cancer 110: 1568–1577.
55. Levina V, Su Y, Nolen B, Liu X, Gordin Y, et al. (2008) Chemotherapeutic
drugs and human tumor cells cytokine network. Int J Cancer (in press).
56. Korkaya H, Wicha MS (2007) Selective targeting of cancer stem cells: a new
concept in cancer therapeutics. BioDrugs 21: 299–310.
57. Samara RN, Laguinge LM, Jessup JM (2007) Carcinoembryonic antigen inhibits
anoikis in colorectal carcinoma cells by interfering with TRAIL-R2 (DR5)
signaling. Cancer Res 67: 4774–4782.
58. Miedouge M, Rouzaud P, Salama G, Pujazon MC, Vincent C, et al. (1999)
Evaluation of seven tumour markers in pleural fluid for the diagnosis of
malignant effusions. Br J Cancer 81: 1059–1065.
59. Kim JJ, Tannock IF (2005) Repopulation of cancer cells during therapy: an
important cause of treatment failure. Nat Rev Cancer 5: 516–525.
Lung CSCs and Cytokine Network
PLoS ONE | www.plosone.org 16 August 2008 | Volume 3 | Issue 8 | e3077
